---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000030"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:38:05.587337+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M

## Summary
- Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.
- Q1 collaboration revenue $12.7M (up from $9.6M); net loss $40.7M ($0.75/share) vs $42.5M ($0.95) YoY.
- Cash and marketable securities $325.6M as of Feb 28, 2023, down from $373.0M at Nov 30, 2022.
- Achieved $7.5M in research milestones from Gilead ($6.5M) and Sanofi ($1.0M) during the quarter.
- Anticipates presenting Phase 1 clinical data for NX-2127, NX-5948, and NX-1607 in H2 2023.

## SEC filing metadata
- accession: 0001549595-23-000030
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/0001549595-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/nrix-20230413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000030
- JSON: https://secwatch.observer/filing/0001549595-23-000030.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000030.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported financial results for first quarter ended February 28, 2023.
  - Period: first quarter ended February 28, 2023
  - Result: reported results
  source text: On April 13, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/0001549595-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.